SOURCE: Regen BioPharma Inc.

April 01, 2015 08:30 ET

Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend

SAN DIEGO, CA--(Marketwired - Apr 1, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:

1. FINANCINGS: The recent issuances of convertible notes by the Company to raise capital have all been converted into common stock. Resales of these shares by noteholders are not permitted for a period of six months from the issuance date of the note. Subsequent to those six months these shares are subject to a "bleed out" provision over an additional 6 months. As of March 31, 2015 there are a total of 109,310,811 common issued and outstanding, with approximately 57,402, 894 ( 52%) of those shares constituting "restricted securities" as the term is defined under Rule 144 promulgated under the Securities Act of 1933. Rule 144 precludes any resales of those shares into the public market until a holding period of at least six months has elapsed since the shares were paid for.

In addition to transfer restrictions imposed under federal law many of these shares are also subject to additional restrictions. Examples of these restrictions include the bleed out provisions applicable to shares issued in conversion of convertible notes and restrictions on transfer applicable to shares issued to employees. For instance, 9,000,000 common shares issued to the Company's CEO and 7,500,000 common shares issued to the Company's CFO are restricted from transfer for a period of 18 months from February 11, 2015. These same restrictions are applicable to 2,500,000 Series A Preferred Shares issued to each of the Company's CEO and CFO.

The above mentioned financings have been essential for the Company to expand and grow, leading towards achievement of Company milestones. Management believes these financings are positive long term for its shareholders as its business model is allowed to be implemented.

2. NEW LABORATORY SPACE: On March 24, 2015 the Company announced acquisition of laboratory facilities. The significance of this announcement was the access to laboratory equipment necessary for the Company to conduct research without spending large sums of money on leasing an empty building and purchasing several million dollars' worth of lab equipment to duplicate facilities the Company has obtained through a modest lease. Common spaces are included but not specifically charged to the Company. This common space area includes: machines for polymerase chain reaction, tissue culture and incubator facilities, vivarium, dark room for molecular biology, analytical room for ultra violet visual light spectrometry, freezer space (-80 degrees and -20 degrees Celsius), autoclave, bench top, molecular biology and ultra-centrifuges along with other numerous equipment / facilities available for research use.

3. PREFERRED STOCK DIVIDEND: On March 25, 2015 the Company paid a 10% stock dividend to shareholders of record on March 10, 2015. This dividend was paid in Regen BioPharma's Series A Preferred Shares. These shares are not convertible into common. The Company anticipates obtaining a symbol specific to the Series A Preferred Shares at the earliest possible date, with the goal of developing a public market for these shares.

4. SCIENTIFIC ADVISOR BOARD EXPANSION (SAB): The Company is currently expanding the SAB to facilitate relationships that will assist in the Company's research. New SAB members are expected to help with protocol development and study design, as well as theoretical approaches to the Company's research areas. The Company is currently in the process of updating its website so that information on new SAB members may be viewed by the public.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer
    619-227-9192 Phone
    619-330-2328 Fax
    www.regenbiopharma.com